Sun Pharma an underperformer: Karvy

Published on Mon, Aug 17, 2009 at 10:41 |  Source : Moneycontrol.com

Updated at Mon, Aug 17, 2009 at 10:44  

21962 Investors following Sun Pharma. Share this News with them.
0
0
Share on Tumblr
Sun Pharma an underperformer: Karvy

RELATED NEWS

ALSO READ

Karvy Stock Broking has maintained its underperformer rating on Sun Pharmaceutical Industries with a target price of Rs 1125 in its August 17, 2009 research report.

"Sun Pharma recently received USFDA approval for generic Eloxatin and Imitrex. Eloxatin is 180 day shared exclusivity. 5 players have approval during the exclusivity period. We maintain our EPS estimates for FY 10E and FY 11E but upgrade our multiple to 16x as compared to 15x earlier and upgrade our price target by 6.6 % to Rs 1125 based on 16x FY 2011E. We however continue to maintain Underperformer rating on the stock," says Karvy's research report.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click on the attachment......

Attachments : Daily 17-08-09.pdf

  

Trending News

Business News

Nokia PureLamda running WP 8.0 pops up on WP Bench app
Why the 'Old Boys' network stands up for Rajat Gupta "Why the 'Old Boys' network stands up for Rajat Gupta"

Vijay century powers CSK into IPL final

Arvind Saxena Says CNBC-TV18 Exclusive Expect 7-8% Growth For Hyundai In Calendar Year 2012

The latest earning numbers FIRST on CNBC-TV18
Videos

May 25 2012, 22:26

Expect single digit growth in ad revenue in FY13: Sun TV

- in Results Boardroom

May 25 2012, 22:26

NHPC posts profit amid capacity addition, delay woes

- in Results Boardroom

Interviews

May 25 2012, 22:00 | Source: CNBC-TV18

Petrol hike on soft global levels is short-sighted: Narayan  

May 25 2012, 15:54 | Source: CNBC-TV18

Capacity debottlenecking led to growth: Shasun Pharma  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!